Hostrup Morten, Kalsen Anders, Bangsbo Jens, Hemmersbach Peter, Karlsson Sebastian, Backer Vibeke
Department of Nutrition, Exercise and Sports, Section of Integrated Physiology, University of Copenhagen, August Krogh Bygningen, 2nd Floor, Universitetsparken 13, 2100, Copenhagen, Denmark,
Eur J Appl Physiol. 2014 Dec;114(12):2499-508. doi: 10.1007/s00421-014-2970-2. Epub 2014 Aug 12.
The purpose of the present study was to investigate the effect of high-dose inhaled terbutaline on muscle strength, maximal sprinting, and time-trial performance in trained men.
Nine non-asthmatic males with a VSO₂max of 58.9 ± 3.1 ml min(-1) kg(-1) (mean ± SEM) participated in a double-blinded randomized crossover study. After administration of inhaled terbutaline (30 × 0.5 mg) or placebo, subjects' maximal voluntary isometric contraction (MVC) of m.quadriceps was measured. After MVC, subjects performed a 30-s Wingate test. Sixty minutes following the Wingate test, subjects exercised for 10 min at 80% of VSO₂max and completed a 100-kcal time trial. Aerobic contribution was determined during the Wingate test by indirect calorimetry. Furthermore, plasma terbutaline, lactate, glucose, and K(+) were measured.
Inhalation of 15 mg terbutaline resulted in systemic concentrations of terbutaline of 23.6 ± 1.1 ng ml(-1) 30 min after administration, and elevated plasma lactate (P = 0.001) and glucose (P = 0.007). MVC was higher for terbutaline than placebo (738 ± 64 vs. 681 ± 68 N) (P = 0.007). In addition, Wingate peak power and mean power were 2.2 ± 0.8 (P = 0.019) and 3.3 ± 1.0% (P = 0.009) higher for terbutaline than placebo. Net accumulation of plasma lactate was higher (P = 0.003) for terbutaline than placebo during the Wingate test, whereas [Formula: see text] above baseline was unchanged by terbutaline (P = 0.882). Time-trial performance was not different between treatments (P = 0.236).
High-dose inhaled terbutaline elicits a systemic response that enhances muscle strength and sprint performance. High-dose terbutaline should therefore continue to be restricted in competitive sport.
本研究旨在调查高剂量吸入特布他林对训练有素男性的肌肉力量、最大短跑速度和计时赛成绩的影响。
9名非哮喘男性参与了一项双盲随机交叉研究，其最大摄氧量（V̇O₂max）为58.9±3.1 ml·min⁻¹·kg⁻¹（平均值±标准误）。在吸入特布他林（30×0.5 mg）或安慰剂后，测量受试者股四头肌的最大自主等长收缩（MVC）。在MVC之后，受试者进行30秒的温盖特测试。温盖特测试60分钟后，受试者以80%的V̇O₂max运动10分钟，并完成100千卡的计时赛。通过间接测热法测定温盖特测试期间的有氧贡献率。此外，还测量了血浆特布他林、乳酸、葡萄糖和钾离子（K⁺）。
吸入15 mg特布他林后30分钟，血浆特布他林的全身浓度为23.6±1.1 ng·ml⁻¹，血浆乳酸（P = 0.001）和葡萄糖（P = 0.007）升高。特布他林组的MVC高于安慰剂组（738±64 vs. 681±68 N）（P = 0.007）。此外，特布他林组的温盖特峰值功率和平均功率分别比安慰剂组高2.2±0.8（P = 0.019）和3.3±1.0%（P = 0.009）。在温盖特测试期间，特布他林组血浆乳酸的净积累高于安慰剂组（P = 0.003），而特布他林对高于基线的[公式：见原文]没有影响（P = 0.882）。两种治疗方法的计时赛成绩没有差异（P = 0.236）。
高剂量吸入特布他林会引发全身反应，增强肌肉力量和短跑成绩。因此，高剂量特布他林在竞技运动中应继续受到限制。
